In the very recent research of Comabella et al., the authors were able to validate CHI3L2 from 10 proteins to be markedly elevated among progressive patients with higher EDSS scores, thus discriminating with good sensitivity and acceptable specificity (90% and 63%, respectively) between high and low disability progression in patients with progressive MS [182]. Here, CHI3L2 is linked to myeloid sarcoma.